Overview
Early HIV identification is critical to help mitigate transmission, begin treatment quickly, and improve patient outcomes. When following recommended guidelines, HIV confirmation testing involves multiple steps and time-consuming test methods. This challenges laboratories to report HIV results quickly and efficiently.
HIV Differentiation — Early Detection, Identification, and Treatment
Unlock fast, efficient HIV testing through the power of multiplex technology. The BioPlex 2200 HIV Ag-Ab panel detects and differentiates HIV antigen and antibodies in a single screening test.
- HIV Ag-Ab (composite result)
- HIV-1 p24 Ag
- HIV-1 Ab (groups M & O)
- HIV-2 Ab
Differentiated results enable early identification of acute HIV and can guide clinical laboratories in the selection of appropriate supplemental testing. Patient results can be reported sooner for immediate initiation of critical treatments.
"The ability to differentiate HIV antigen and antibody results in screening tests could enable improved testing algorithms that will reduce the time to confirmation and ultimately improve clinical care."
Tom S. Alexander, PhD, D(ABMLI)
Clinical Laboratory Director, FlowMetric Diagnostics
Optimize HIV Testing Processes
Discover how the BioPlex 2200 HIV Ag-Ab panel revolutionizes the management of HIV testing and confirmatory algorithms.
-
Image
Patient A: Negative Result -
Image
Patient B: HIV-1 p24 Ag Positive Result -
Image
Patient C: HIV-1 Ab (Group M & O) Positive Result -
Image
Patient D: HIV-2 Ab Positive Result
Streamline HIV Diagnosis
Differentiated HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody results provide more information at the screening level. This can help guide your lab in the selection of appropriate confirmatory testing.
Reduce Confirmation Testing
Are you frustrated by the unnecessary time spent confirming false-positive results? The BioPlex 2200 HIV Ag-Ab panel features excellent clinical specificity to help minimize false-positive results. This means fewer supplemental tests, less work for laboratory technologists, and less stress for physicians and patients.
Maximize Efficiency and Minimize Effort
Traditional HIV tests may require numerous manual processing steps. But with the fully automated BioPlex 2200 System, your technologists can complete HIV testing workloads with less hands-on time. Simply load the samples and walk away.
Case Study: Monthly Labor Time Comparison
See how you can reduce labor costs and make optimal use of medical laboratory technologists — your lab’s most valuable resource.
This case study compares manual processing time of the BioPlex 2200 HIV Ag-Ab panel to a competing fully automated HIV test. Data are based on an actual lab’s monthly HIV screen volume.
In total, 34% less hands-on time was required with multiplexing than with the competing test.
For a personalized workflow analysis of your lab, please contact your
Bio-Rad representatives.
Improve Patient Care
Better patient outcomes depend on early HIV detection plus fast confirmation and result reporting. The BioPlex 2200 HIV Ag-Ab panel allows your lab to have both.
Detect Acute HIV Early to Minimize Transmission
The BioPlex 2200 HIV Ag-Ab panel enables the earliest possible HIV serology detection with extraordinary analytical sensitivity¹ and clinical seroconversion detection up to five days earlier than the most sensitive competing HIV tests.² By identifying acute HIV early, labs can help patients minimize HIV transmission.
Streamline HIV Diagnosis for Improved Patient Outcomes
Through multiplex technology, the BioPlex 2200 HIV Ag-Ab panel differentiates HIV antigen and antibodies in a single screening test. Differentiated results guide laboratories in selecting appropriate HIV supplemental testing.
Prevent Further Transmission
Acute HIV is the most infectious phase of HIV infection. By differentiating HIV-1 p24 Ag at the screening level, labs can streamline confirmation steps, report results faster, and help patients prevent further transmission.
Treat Patients Quickly
Earlier HIV diagnosis enables physicians to administer critical antiretroviral therapies sooner, significantly improving patient outcomes.
Confidence in EVERY Patient Result
In addition to external independent quality controls, patented quality control beads are integrated into the BioPlex 2200 HIV Ag-Ab Panel. This enables the real-time analysis of assay parameters for every test, providing additional confidence in every patient result.
Minimize Costs
Current HIV testing algorithms require multiple tests to confirm HIV-positive screening results — tests that can be labor intensive and very expensive. The BioPlex 2200 HIV Ag-Ab panel can help your lab optimize testing processes and minimize costs.
Streamline Confirmation Steps
Differentiated HIV antigen and antibody screening results guide laboratories in selecting appropriate confirmatory testing. By streamlining HIV confirmation steps, labs can save considerable labor, reagent, and send-out testing costs.
Reduce False-Positive Results
Because confirmation testing is costly and time consuming, preventing false-positive results is essential. The excellent specificity of the BioPlex 2200 HIV Ag-Ab panel helps reduce false-positive results to minimize repeat and supplemental testing costs.
Want to learn more about reducing false-positive results?
This webinar summarizes a specificity study that analyzed over 150,000 specimens collected over a 49-month period.
- Data on file at Bio-Rad Laboratories.
- Data on file at Bio-Rad Laboratories and at investigating laboratories. Adapted from data originally provided by ZeptoMetrix. ZeptoMetrix Corporation (2019). HIV Seroconversion Panel Donor No. 73698, Part Number HIV12008. https://web-resources-prod.zeptometrix.com/documents/public/PI/PIHIV12008.pdf, accessed 10/14/2024.
Complementary Products
-
-
Quality Control Products
External quality controls may be used to independently monitor the performance of test methods.
Ordering
items
Use the filters below to refine results!
Reagents for 200 samples for multiplex detection and differentiation of HIV-1 p24 antigen and antibodies to HIV-1 (Groups M and O) and HIV-2 on the
Three sets of multiplexed standard analytes for calibration of results of HIV-1 p24 antigen and antibodies to HIV-1 (Groups M and O) and HIV-2 on the
Three sets of multiplexed negative and positive controls for multiplex detection and differentiation of HIV-1 p24 antigen and antibodies to HIV-1 (Groups M and O) and HIV-2 on the BioPlex 2200 System